BioSpace News Archive

IN8bio, Inc. (Nasdaq: INAB) today announced positive early data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic gamma-delta T cell therapy, in patients with high-risk acute myeloid leukemia (AML) undergoing haploidentical hematopoietic stem cell transplant (HSCT) have been selected for a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022.

Kyowa Kirin, Inc. announced the publication of Burden and Benefit: Embracing the duality of the Parkinson’s caregiving experience, a whitepaper that explores the caregiving experience, featuring insights from the 2022 Parkinson’s Care Partner Survey and advice from advocates and care partners on how to plan for the road ahead.

AlloVir, Inc. announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses following allogeneic hematopoietic cell transplantation has been accepted as an oral presentation at the 64th American Society of Hematology Annual Meeting to be held in New Orleans, Louisiana, December 10-13, 2022.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that an abstract detailing updated safety and efficacy data from the Company’s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL) was made available as part of the 64th American Society of Hematology (ASH) Annual Meeting.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have a poster presentation for ALPN-303’s phase 1 study (RUBY-1) at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.

Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced positive interim data from its Phase 2b clinical trial with denifanstat, a fatty acid synthase inhibitor, in non-alcoholic steatohepatitis patients.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces upcoming data presentations at the 75th American Heart Association (AHA) Annual Meeting, taking place in Chicago, Illinois, and virtually, from Nov. 5-7, 2022, and the 64th American Society of Hematology (ASH) Annual Meeting.

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) announced today that three abstracts related to the Company’s rusfertide program have been accepted as poster presentations at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 10-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Genentech, a member of the Roche Group, announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting taking place from December 10-13 in New Orleans, Louisiana.